JelikaLite is a biotechnology company in New York City that is developing individualized solutions for children with autism, a complex condition that is characterized by problems with communications, behavior, and social skills. According to the U.S. Centers for Disease Control and Prevention (CDC), the estimated prevalence of autism has risen from 1 child per 166 in 2004 to 1 child in 54 in 2020.
Katya Sverdlov, CFA, Esq., Chief Executive Officer of JelikaLite, recently spoke with NYS Manufacturing Now about the company’s efforts to literally light the way to a brighter future. Photobiomodulation (PBM) therapy, JelikaLite’s core technology, is an innovative red / near infrared light treatment that has been shown to have beneficial effects on children and adults diagnosed with autism spectrum disorder (ASD).
A Commercialization Competition grant from FuzeHub’s Jeff Lawrence Innovation Fund is helping to fund JelikaLite’s product development, the subject of our latest podcast.